Janssen

Ustekinumab could be approved to treat ulcerative colitis

7 January 2019 | By European Pharmaceutical Review

Ustekinumab has been submitted to be the first interleukin (IL)-12/23 inhibitor licensed for the treatment of ulcerative colitis...